Alimera Sciences Cancels IPO

Alimera Sciences Inc., an Atlanta-based ophthalmic pharmaceutical company, has withdrawn registration for a $75 million IPO, due to “current public market conditions.” It had planned to trade on the Nasdaq, with Credit Suisse and Citi serving as co-lead underwriters.

Alimera has raised just over $71 million in VC funding since 2004, from firms like Scale Venture Partners (18.27% pre-IPO stake), Domain Associates (18.27%), Intersouth Partners(18.27%), Polaris Venture Partners (18.27%) and Venrock Associates (14.8%).

It also received a total of $16.7 million from the sale of two OTC allergy products and a lubricating eye from to Bausch & Lomb. www.alimerasciences.com

Related Posts

Leave a Reply

PEHUB Community

Join the 12501 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget